The childhood vaccine schedule, compared

The US vaccine schedule is bigger. The comparison to peer countries leaves out why.

Today the President signed an executive order declaring the American childhood immunization schedule an "outlier" and reorganizing it into three tiers, with 11 diseases recommended for all children instead of 18, and the combined MMR shot split into three separate single-disease shots at separate visits. The order rests on an HHS assessment that says the US recommends "more childhood vaccines than any peer nation, including more than twice as many vaccine doses as some European nations." The comparison is real, but so is what it leaves out: which countries, why their schedules differ, and the fact that the system being judged has a different task than the ones it is judged against.

The short version

The US immunization schedule recommends more vaccines than peer countries, and the executive order uses that gap as evidence the schedule is excessive. But the countries it is compared to have different disease burdens: the US gives a hepatitis B shot at birth because an estimated 17,827 infants were born to infected mothers in 2021 and the federal program built to find them identifies fewer than half, while several peer countries with lower prevalence vaccinate only the infants of mothers who test positive. They have different health systems: every peer country on the comparison list has universal healthcare, so every child has a medical home, every dose is recorded in a national registry, and no parent pays out of pocket for the visit. And they have different delivery mechanisms: the US relies on school-entry mandates to catch the children a national health service would have reached on its own. The order also directs that the combined MMR shot be split into three single-disease shots given at separate visits, which triples the injections and the visits required for the same protection, using products that do not exist in the US. The order bans no vaccine and pulls none from the market; what it changes is which vaccines the federal government recommends for every child, and what it advises states to require.

The order

What the executive order says, and what the fact sheet adds. #

The executive order was signed August 10, 2026. Its title is "Delivering Gold Standard Childhood Vaccine Recommendations for Americans." It is the third action in this series: a presidential memorandum in December 2025 ordered HHS to produce a "scientific assessment" comparing the US schedule with peer nations, a May 2026 executive order directed the CDC to update the schedule accordingly, and this one does it directly after litigation delayed the CDC process. (White House, August 10, 2026) Documented

The order establishes three categories of vaccines, replacing the 18 diseases the CDC recommended for children in 2024:

The order's three categories

"Recommended for all children": measles, mumps, rubella, diphtheria, tetanus, pertussis, polio, Haemophilus influenzae type B, pneumococcal disease, human papillomavirus, and varicella. That is 11 diseases.

"Recommended for certain high-risk groups or populations": RSV monoclonal antibodies, hepatitis A, hepatitis B, meningococcal B, meningococcal ACWY, and dengue.

"Based on shared clinical decision-making": hepatitis A, hepatitis B, rotavirus, meningococcal disease, influenza, and COVID-19.

The accompanying fact sheet put the numbers in historical terms the order itself does not: "In 1980, American children following the CDC immunization schedule received 23 vaccine doses in 7 shots against 7 different diseases. In 2024, the recommended number of routine vaccines had risen to at least 84 vaccine doses in at least 57 shots for 17 diseases, plus the RSV monoclonal antibody immunization for a total of 18 diseases. This is more than other developed nations." (White House fact sheet, August 10, 2026) Documented

The comparison to 1980 illustrates a real trend: the schedule is larger by any measure. Whether that is a problem depends on whether the added vaccines prevent diseases that matter. In 1980 the Hib vaccine did not exist. Neither did the hepatitis B vaccine, the chickenpox vaccine, the pneumococcal conjugate vaccine for children, or the HPV vaccine. Each one of those was invented because a disease was killing or disabling children. The number of shots rose because the number of diseases medicine learned how to prevent rose. That does not mean every addition was equally urgent, but it does mean the rise was driven by invention, not inflation.

The reason in the order, and the reason given out loud

The order's written rationale is the peer-country comparison. The rationale offered at the signing was different. Speaking about the combined MMR shot, the President said: "There could be a possibility they're quite lethal, and separately, it looks like they are not at all lethal but just very effective." Asked by a reporter whether he had evidence that the combined shot was lethal, he said he did not, and said he had heard it from other people. (Scientific American; Deseret News, both August 10, 2026) His claim

There is no evidence that the combined MMR shot is lethal, and the President did not claim to have any. That distinction matters for reading the rest of the order, because the peer-country comparison and the lethality claim are not the same argument. The first is a real finding that can be examined. The second is not a finding at all. This page examines the first one, because that is what the order is built on and it is the one worth taking seriously.

He was also explicit about what the order leaves in place: "Parents can still choose to give their children all of the vaccinations if they wish. It's up to the parents." That is accurate, and it is worth stating plainly before going any further. Holds up

What the order does not do It does not ban a vaccine, withdraw one from the market, or make one unavailable. It does not repeal any state law. It does not change the schedule published by the American Academy of Pediatrics, which pediatricians actually work from, and it does not by itself change what insurers cover. What it changes is which vaccines the federal government recommends for every child, which ones it moves into narrower tiers, how they are packaged and spaced, and what it advises states to require for school entry. Those are real changes with real consequences, argued below. They are not a prohibition, and this page does not describe them as one.

Two things the order does that sit outside the peer-country comparison but define its practical effect: it directs that the combined MMR shot be split into three separate single-disease vaccines administered at separate visits, and that "to the maximum extent feasible, all childhood immunizations should be administered at separate medical visits." The products for separate measles, mumps, and rubella shots do not exist domestically. The order directs HHS to work with the private sector to create them. Those two provisions are addressed further down.

Ask the desk "What did the HHS scientific assessment actually find?"

The comparison

Which countries, and what differs. #

The executive order and its fact sheet name the finding that the US schedule is an "outlier" and that it recommends "more than twice as many vaccine doses as some European nations." Neither names which European nations, which vaccines differ, or why they differ.

The HHS assessment compared the US schedule against Australia, Canada, France, Germany, Italy, Japan, the Netherlands, New Zealand, Norway, Spain, Sweden, Switzerland, and the United Kingdom. That is the standard set of OECD peer countries used for health-policy comparisons, and using them is reasonable. The problem is not the list. It is what the comparison skips. Documented

What is different about the diseases

The diseases the US vaccinates against that some peer countries do not are not random. Some of them are present in the United States at rates the comparison countries eliminated, some of them pose a different risk because of how the population is structured, and some of them the comparison countries do vaccinate against but in a different way. The following table is not exhaustive. It covers the largest differences.

Differs
Hepatitis B at birth The US recommends a birth dose because an estimated 17,827 infants were born to hepatitis B positive mothers in 2021. Without treatment within hours of birth, roughly 90 percent of those infants would acquire chronic hepatitis B, which carries a lifelong risk of liver failure and liver cancer. The birth dose combined with immune globulin is about 94 percent effective at preventing that. Many European countries with lower prevalence do not give a universal birth dose. The UK, for example, vaccinates only infants whose mothers test positive. A natural question is why the US does not do the same, since all pregnant women are supposed to be screened. The answer is in the CDC's own review of the birth dose: 12 to 16 percent of pregnant women have no record of being tested at all, about 15 percent receive inadequate or no prenatal care, screening tests are sometimes misread, and postexposure treatment is sometimes not given even when the mother's status is known. The federal program built to identify these infants reaches fewer than half of the number estimated to be born each year. The birth dose is what covers the gap. An infant who acquires hepatitis B has roughly a 90 percent chance of chronic infection; about 95 percent of infected adults clear it completely. Imperfect screening, a catastrophic outcome for a missed case, and a vaccine with a long safety record make a universal birth dose a different calculation in the US than in a country with both lower prevalence and universal prenatal tracking. (CDC; CDC hepatitis B birth dose briefing, ACIP, September 2025; UK Health Security Agency) Documented
Differs
Rotavirus Before the vaccine, rotavirus hospitalized roughly 50,000 to 70,000 young children a year in the US. It rarely killed them, which is why peer countries weighed it differently: where a hospital stay costs the family nothing, the case for universal vaccination rests on the hospitalization itself rather than on the bill. Europe has largely converged on the US position since. As of 2023, 25 countries in the WHO European Region had universal infant programs, and Austria, Belgium, Finland, Germany, Sweden and the UK all exceed 80 percent coverage. The most instructive exception cuts against this page's argument, and is worth stating plainly. France recommended universal rotavirus vaccination in 2013, then suspended that recommendation in April 2015 after 47 reported cases of intussusception, a serious bowel obstruction, including 14 that required surgery and two deaths. That is a peer country removing a vaccine from its schedule over a specific safety signal, which is the kind of review this order says it wants. What followed matters too: a benefit-risk analysis published afterward estimated that even at France's low coverage, vaccination prevented roughly 1,074 hospitalizations and 1.4 deaths a year while causing about 5 hospitalizations and 0.005 deaths from intussusception. France recommended universal vaccination again in 2022. (CDC; Benefit-risk analysis of rotavirus vaccination, France, 2015; The Value of Rotavirus Vaccination in Europe) Documented
Differs
Varicella (chickenpox) The US has recommended universal childhood chickenpox vaccination since 1995. Several European countries, including the UK until recently, did not. The reason is not that they considered the vaccine unnecessary: it is that chickenpox in a country with universal healthcare and paid sick leave is a different calculation than in one where a parent missing work to care for a sick child can mean lost wages. The UK's Joint Committee on Vaccination and Immunisation recommended adding it in November 2023, and the NHS began administering it in 2024. (UK Department of Health, 2023) Documented
Differs
Influenza (annual, all children) The US recommends annual flu vaccination for everyone six months and older. Most European countries recommend it only for high-risk children and the elderly. The American case does not rest on a global figure: in the 2024-25 season the CDC recorded 280 influenza-associated deaths among US children, the highest total since this reporting began, other than the 2009-10 pandemic year. Among those who were old enough to be vaccinated and whose vaccination status was known, 89 percent were not fully vaccinated. The broader recommendation also exists because the US does not have a system that can reliably identify and reach every high-risk child without one. (CDC, MMWR, 2025; ECDC) Documented
US only
What the US does NOT vaccinate against that some peers do The comparison also runs the other way. Several peer countries vaccinate against tuberculosis (BCG) for all newborns. The US does not, because TB prevalence is low enough that the risk of the vaccine outweighs its benefit for the general population. Japan vaccinates against Japanese encephalitis. The UK vaccinates against meningococcal B for all infants, which the US now lists as "high-risk groups" only. A country's schedule reflects what is in the country. Schedules differ in both directions.

The fact sheet says the US schedule covers 18 diseases and the new "Gold Standard" covers 11, but several of the removed diseases appear in both the "high-risk" and "shared clinical decision-making" categories. Hepatitis A and hepatitis B appear in both. Meningococcal disease appears in both. The three categories overlap, so the count from 18 to 11 is not a subtraction of seven unique diseases from the schedule. It is a reclassification into tiers that keep some of the same vaccines available under different labels.

Ask the desk "How does Japan's vaccine schedule compare to the US and why?"

The system

A narrower schedule assumes a system that finds every child. The US does not have one. #

The executive order's fact sheet notes that "most peer nations maintain high childhood vaccination rates through public trust and education" rather than school-entry mandates, and that "the US is among a minority of peer nations with childhood vaccine mandates." That is true. The mechanism it omits is why.

Every country on the HHS comparison list has a national health system in which a child's vaccinations are tracked, scheduled, and administered at no out-of-pocket cost to the parent through a single system. A child in the United Kingdom is registered with a general practitioner at birth, called in for well-child visits by the NHS, and vaccinated as part of a universal schedule managed by a single agency. A child in the Netherlands receives vaccinations through municipal health services that actively reach out to families. A child in Norway or Sweden is tracked in a national immunization registry from birth.

The United States has none of these things. It has a patchwork of private insurance, Medicaid (which varies by state), the Children's Health Insurance Program, the Vaccines for Children program (which provides vaccines at no cost to eligible children but does not pay for the visit to administer them), and roughly 4 million uninsured children. There is no national registry that tracks every child's vaccination status. There is no single agency responsible for making sure a child in rural Montana or urban Detroit gets every dose on schedule.

School-entry mandates are the backstop. They are what catch the children who slip through the cracks of a fragmented system. A parent who misses a well-child visit is reminded when the school says the child cannot enroll without the shot. The mechanism is blunter than a national health service, and it exists because the alternative is children going unvaccinated. The order advises states to "consider updating relevant laws and regulations that define the scope of immunization requirements for contexts such as school enrollment," which means weakening the backstop without building anything to replace it.

4 million

Uninsured children in the United States in 2024, roughly 5 percent of all children. They are eligible for the Vaccines for Children program, which covers the cost of the vaccine itself but does not cover the doctor's visit to administer it. In a country with universal healthcare, that distinction does not exist. (KFF) Estimate

Ask the desk "What happens to vaccination rates when school mandates are removed?"

The MMR split

Two shots that prevent three diseases, ordered split into six. #

Section 2(b) of the executive order would reshape how the most effective pediatric vaccine in the schedule is delivered. The order declares that "the combined measles, mumps, rubella (MMR) vaccine should be administered in three separate single-disease shots once such products are domestically available and that, to the maximum extent feasible, all childhood immunizations should be administered at separate medical visits."

The combined MMR vaccine is one of the most studied medical products in history. Two doses are roughly 97 percent effective against measles, 88 percent against mumps, and 97 percent against rubella. It has been given to hundreds of millions of children since 1971 with a safety record that the CDC, the WHO, and the European Medicines Agency describe as well established. The combined shot means a child gets two injections to be protected against three diseases. (CDC) Documented

The order would replace this with something for which the products do not exist. Single-disease measles, mumps, and rubella shots are not manufactured for the US market. The order directs HHS to "offer options to administer core childhood vaccines, starting with MMR, as single vaccines rather than combination products/doses, including by working with the private sector and other countries." Creating, testing, and licensing three new products takes years.

The arithmetic is worth doing explicitly, because both sides of this argument have been loose with it. The current schedule protects a child against all three diseases with two injections, one at roughly 12 to 15 months and one at 4 to 6 years. Split into single-disease products and administered at separate visits, the same protection requires six injections across six visits. The number of diseases prevented does not change. The number of needle sticks and clinic trips triples.

The sharpest version of that objection came not from a public health agency but from a Republican physician in the Senate. Sen. Bill Cassidy (R-LA), a gastroenterologist who sits on the Senate health committee, wrote that "Breaking up vaccines will mean children will have to get more shots to get the same protection, not fewer shots. It will increase hesitancy and make children less safe." He added that "The President does not have the expertise to make these changes," said of the order "this is so wrong," and told parents to listen to their pediatricians. (Deseret News, August 10, 2026) Documented

What combination vaccines exist for

Combination vaccines are not a convenience feature. They exist for three reasons that were learned the hard way.

1. Every additional visit is a child who may not come back. The clearest US evidence is a study of 18,821 infants in Georgia's Medicaid program: those whose providers used combination vaccines had higher coverage rates across the DTaP, polio and MMR series than those who received no combination products, and the difference held after adjusting for demographic and provider factors. The reason is straightforward: a parent who has to bring a child to the clinic six times instead of two is a parent who may miss one of them. (Marshall GS et al., Pediatric Infectious Disease Journal, 2007) Documented
2. Delaying protection means unprotected time. If MMR doses are split, a child who gets a measles shot at one visit, a mumps shot at the next, and a rubella shot at the third is unprotected against mumps and rubella during the gap. The combined shot protects against all three at once. The order's preference for "separate medical visits" would multiply these windows.
3. More injections mean more pain, more fear, and more parents who hesitate. This one needs calibrating, because it is easy to overstate and this page will not. Parents do place real value on fewer injections; a willingness-to-pay study found they would pay a meaningful amount to spare a child the pain and distress of extra shots. But in surveys of hesitancy, the number of injections ranks below other worries rather than above them. One point-prevalence survey found 36 percent of parents concerned about side effects, 20 percent about safety in general, and 13 percent about the number of vaccines given. In the same survey 31 percent said they would prefer fewer vaccines at one time, and of those, 78 percent said they would still vaccinate a future child. The concern is real and common, and it is usually not what stops a parent. What the order does with it is the problem: it builds the schedule around the concern rather than addressing it. (Meyerhoff et al., Pediatric Infectious Disease Journal, 2001; Marshall S et al., Pharmacy, 2021) Estimate

Ask the desk "What evidence is there that separate vaccine visits lower completion rates?"

The count

How the US schedule got to 84 doses, and what the count leaves out. #

The fact sheet's figure of 84 doses across 18 diseases is eye-catching. But counting vaccine doses in the US schedule against those in a peer country schedule is like counting the number of pills in two medicine cabinets and concluding the fuller one is excessive. It does not tell you what the pills are for, whether the people in each house have the same illnesses, or whether one house even has a doctor making the rounds.

Several of the differences in dose counts are structural and have nothing to do with whether the schedule is "excessive."

DTaP is given at five intervals because immunity to pertussis wanes. The UK also gives a pertussis-containing vaccine five times. So do France, Germany, and Australia. This is not a US outlier.
Hepatitis B is three doses and the US gives a birth dose. Many low-prevalence European countries do not give a universal birth dose because perinatal transmission is rarer there, not because the US schedule is incorrect for the US disease burden.
The US recommends annual flu vaccine for all children starting at six months. Most European countries limit flu vaccination to high-risk children and do not count those doses in their total, because a selective recommendation has fewer doses by design. The total depends on who is counted.
COVID-19 vaccination recommendations vary widely. The US recommended it for all children in 2024; several European countries limited it to high-risk groups even then. The count depends on what point in time a snapshot is taken, and COVID recommendations have narrowed across all countries since the acute phase of the pandemic.
What the count does get right There is a genuine difference, and the HHS assessment identified it correctly: the US schedule is larger than the peer-country average. That is not in dispute. The question is whether the reason is excess or epidemiology. The same assessment that found the US is an outlier also found a set of "consensus vaccines" recommended in all peer countries. The executive order uses that consensus set as its "recommended for all" tier: 11 diseases. But "consensus" means every country agrees on them; it does not mean every country would be equally safe stopping there. A country with a hepatitis B problem does not become safer by matching the schedule of a country without one.

Ask the desk "What would happen to US measles rates if vaccination dropped 3 percentage points?"

The best case for the order

Five things the order gets right, or close to right, and what survives checking them. #

1. The US schedule really is larger than every peer nation's. That is a fact, and the article has not disputed it. A US child receives vaccination against more diseases and through more doses than a child in any comparable wealthy democracy. The factual observation that prompted the EO is correct. The question is what the fact means, and whether "larger" is the same thing as "excessive." That question cannot be answered by counting doses alone, but it also cannot be answered by denying the count. Where this goes: the count is real. The inference that more doses equals a worse schedule is the leap the evidence does not support.
2. The ACIP process has structural features that favor addition, not subtraction. This is the single strongest argument for external review, and the article should not wave it away. ACIP members often have research ties to the diseases they study. Manufacturers develop products and seek recommendations. And the burden is asymmetric: a member who votes to add a vaccine is adding protection; a member who votes to remove one is potentially responsible for every case that follows. There is no formal process within ACIP for periodically re-evaluating whether existing recommendations should be removed from the universal schedule. Peer nations handle this differently: the UK's JCVI is statutorily independent of NHS England, and Germany's STIKO operates with formal independence from the Robert Koch Institute. A review that asks whether every item still belongs is reasonable. Where this goes: the ACIP process is not above criticism. But the remedy is a better process, not an executive order that bypasses the existing one entirely and declares the outcome in advance.
3. School-entry mandates in a country without universal healthcare are a crude tool. They are also the only tool the US has to ensure children who do not have a regular doctor still get vaccinated. Sweden achieves roughly 97 percent MMR coverage without any school mandates, using universal child health centers, a national vaccine registry, and zero cost to parents. The US, with its full apparatus of school-entry requirements, manages about 93 percent. That gap is real, and it suggests school mandates alone are not enough. But removing mandates without building Sweden's universal tracking and single-payer delivery would almost certainly make coverage fall further, not rise. The order weakens the tool without building the mechanism.
4. Parents should be able to choose the timing and spacing of vaccines, not just whether to get them at all. The current schedule bundles decisions together in a way that removes granular choice. A parent who wants to space out vaccines or observe a child's reaction to one before administering another has limited ability to do so within the standard schedule. This is not about refusing vaccines. It is about wanting more control over how they are delivered. Where this goes: the concern is real, and it is one of the most common reasons parents give for hesitancy. But the evidence on what happens when spacing increases is consistent and clear: more visits means more missed doses, and the children most likely to fall behind are those already at greatest risk. A system that genuinely wanted to address this concern would build the universal tracking, proactive outreach, and reminder infrastructure that makes flexible scheduling safe. The order does none of those things.
5. The cumulative load of antigens and adjuvants is a legitimate scientific question, not a conspiracy theory. It is the single most common concern among hesitant parents, and dismissing it as anti-vaccine propaganda misses why so many reasonable people ask about it. The scientific answer is that infants encounter orders of magnitude more novel antigens through daily environmental exposure than through any vaccine schedule, and multiple large studies have found no association between the number of vaccines received and adverse outcomes. But the concern is not unreasonable on its face: asking whether 84 doses of anything is too much for an infant immune system is a legitimate question. It is also a question that has been studied, repeatedly, by immunologists who concluded the immune system's capacity vastly exceeds the load the schedule places on it. (Offit et al., Pediatrics, 2002) Where this goes: the question is real, and it has been tested at scale. A Danish study published in 2025 followed 1.2 million children born between 1997 and 2018 and found no association between cumulative aluminum exposure from vaccines in the first two years of life and any of 50 chronic conditions, including autism, asthma and autoimmune disease. On the order's own text, Section 3(c) directs HHS to "develop additional alternative adjuvants to aluminum and conduct comparative safety and efficacy studies." Developing alternative adjuvants is ordinary research and this page will not pretend otherwise. What the order does not do is name what result would settle the question, or engage the evidence that already exists. (Offit et al., Pediatrics, 2002; Andersson et al., Annals of Internal Medicine, 2025)

There is also a sixth argument that has force but is not in the order: the US does have worse population health outcomes than peer countries on several measures including infant mortality and life expectancy. That gap is driven by preterm birth, socioeconomic inequality, and healthcare access disparities, not by vaccination policy. Using it to justify a smaller vaccine schedule is an ecological fallacy. But the fact that the US spends far more and gets worse outcomes is a real and important indictment of American healthcare. It is not what this executive order is about.

Ask the desk "What do vaccine-skeptical scientists who are not anti-vaccine actually argue?"

Honest limits

What this page does not claim. #

Every vaccine in the US childhood schedule has side effects, most of them mild (fever, soreness at the injection site, fussiness) and a very small number of them serious. This page does not claim that every vaccine is risk-free. No medical intervention is.

This page does not claim that the US schedule is perfect or that no vaccine could ever be removed. The ACIP process that sets the schedule includes continuous review, and vaccines have been withdrawn before: the original rotavirus vaccine was pulled in 1999 after it was linked to a rare form of bowel obstruction, and a safer replacement was developed. Smallpox vaccination ended in 1972 after the disease was eradicated. The oral polio vaccine was replaced with an inactivated version in 2000 once the live vaccine's residual risk exceeded the vanishing risk of wild polio. Each removal followed a specific change in circumstances: a safety signal, eradication, or a shift in the risk-benefit calculus. The executive order cites none of these. It cites a comparison to peer countries. Reviewing the schedule is normal. Reviewing it by executive order against a peer-country comparison that ignores why the peers differ is not.

This page does not claim that the childhood immunization schedule has been studied as a complete sequence against a control group. It has not. The National Academies noted in 2013 that "few studies have attempted more global assessments of entire sequence of immunizations or variations in the overall immunization schedule" and recommended that HHS prioritize whole-schedule safety research. That gap is real and worth filling. It does not mean the schedule is unsafe. It means the evidence for the schedule as a whole relies on the accumulated safety data of its individual parts, which is strong, and on the absence of signals in decades of post-market surveillance. A gap in evidence is not the same as evidence of a problem.

This page does not claim the countries compared have worse health outcomes because of their shorter schedules. They do not. Their schedules are appropriate for their disease burdens and their health systems. The point is that a schedule designed for one country cannot be judged against the schedule of another without accounting for what is different about the country.

This page does not claim the order is unlawful. An executive order is within the president's authority, and the order's own text says it "shall be implemented consistent with applicable law." The question is whether the order's reasoning holds, not whether the president may issue it.

This page cites the CDC, the WHO, and professional medical organizations as authorities. Those organizations receive funding from the pharmaceutical industry, which is a real structural concern documented in the peer-reviewed literature, and their positions should be evaluated on the evidence they present, not on institutional authority alone.

Ask the desk "Has the US ever removed a vaccine from the childhood schedule before?"

What the claim costs

A comparison that judges the US schedule against countries it does not resemble will produce a schedule that does not protect the country it serves. #

The executive order is built on a real finding: the US schedule is larger than those of peer countries. That finding does not, on its own, tell you whether the schedule is too large or whether the peers have too little. To answer that question you need to know whether the diseases being vaccinated against are present in the United States at rates that justify vaccination. You need to know whether the country has a health system that can reliably deliver a narrower schedule to every child who needs it. You need to know whether the mechanism the order weakens (school-entry mandates) has a replacement that can do the same job without it.

On all three, the order is silent. The diseases the peer countries do not vaccinate against are in many cases diseases they have eliminated or never had at the same prevalence. The health system those countries use to achieve high vaccination without mandates is one the United States has never built. And the school mandates the order tells states to reconsider are the only mechanism the United States has for catching the children a universal system would have reached on its own. A narrower schedule, delivered by a system with weaker mandates and no replacement infrastructure, will leave more children unvaccinated. Unvaccinated children get sick. The diseases this order would stop routinely protecting against have not gone anywhere. They are waiting for the coverage to drop.

The order also directs something with no real precedent in peer countries. Splitting MMR into six injections across six visits maximizes the number of visits, the number of injections, and the number of opportunities for a child to fall behind. The countries the US is being compared to use the same combined shot on the same two-dose schedule, because their experts reached the same conclusion the CDC's did. The closest counterexample is Japan, which uses a combined measles-rubella shot plus a separate mumps vaccine, not three separate shots. That separation has a specific cause: the Urabe strain used in Japan's MMR caused aseptic meningitis at a rate of roughly 16.6 cases per 10,000 recipients, and Japan withdrew the combined shot in 1993. Mumps vaccination there became voluntary and parent-funded, and coverage fell from nearly 90 percent to roughly 30 to 40 percent, with recurring mumps outbreaks since. Japan is a warning about what happens after a combined vaccine is broken up, not a model for doing it.

A country's vaccine schedule reflects the diseases in the country, the system that delivers care, and the gaps that system leaves. That does not make every difference justified. Each vaccine on the US schedule was added for a reason, and some of those reasons may have aged out. The honest way to find out is to ask about each one specifically: does the disease still circulate here, does the delivery system still need the vaccine in the schedule, does the protection still outweigh the cost? France asked that question about rotavirus, suspended it, then answered the question and restored it. That is what a review looks like. This order does not ask it. It counts doses in other countries and stops. The gap is real. The excess is not.

Sources #

The executive order and supporting documents

Vaccine schedules and recommendations

Disease burden and vaccine safety evidence

Healthcare systems and access

Combination vaccines and visit compliance

News coverage of the executive order

Methods note

Every claim on this page is attributed and labeled: Documented on a regulatory, official, or peer-reviewed record; His claim asserted by the administration and not independently corroborated; Estimate from a survey or model; Holds up a statement by the administration that checking confirms. The executive order is quoted from whitehouse.gov, with section numbers as they appear in that text. The HHS scientific assessment was published in January 2026 and is cited as the basis for the order's peer-country comparison. Quotations from the President and from Sen. Cassidy are taken from the outlets named beside them; where a remark was reported in a reporter's own words rather than as a direct quotation, this page reports it the same way, without quotation marks. This page does not claim the CDC schedule is beyond review, that every individual recommendation is optimal, or that the order prohibits any vaccine. The argument is that comparing schedules without comparing the countries they serve answers the wrong question.

Read next

Public healthHe gave four reasons to defund mRNA. Not one of them holds.
Public healthThey promised the cause of autism by September. What they delivered was an instruction their own FDA never gave.